Stereotactic body radiotherapy (SBRT) and hypofractionated conventional radiotherapy led to similar tumor control and survival outcomes at 3 years in patients with peripheral and central stage I ...
Daiichi Sankyo announced that the first patient has been dosed in the global phase 3 TROPION-Lung17 trial. The study is evaluating DATROWAY in patients with locally advanced or metastatic nonsquamous ...
Eli Lilly’s oral targeted cancer therapy, Retevmo, has shown benefit as an adjunctive therapy in a Phase III trial in patients with early-stage (II-IIIA) rearranged during transfection (RET) ...
This press release is not intended for UK mediaHERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as ...
For years, the default definitive treatment for patients with early-stage I non–small cell lung cancer (NSCLC) has been surgical resection, typically minimally invasive lobectomy with systematic lymph ...
Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 LIBRETTO-432 clinical trial of Retevmo (selpercatinib) as adjuvant therapy versus placebo. The study met its ...
Adjuvant selpercatinib boosts event-free survival after surgery in early-stage RET fusion-positive NSCLC, signaling a ...
Ask a clinical question and tap into Healio AI's knowledge base. Lung cancer in general, and non-small cell lung cancer (NSCLC) in particular, is often asymptomatic in the early stages of the disease.
You and your family are our top priority. At Fred Hutch Cancer Center, we offer comprehensive and compassionate care — personalized to you. You'll have access to the latest treatment options, clinical ...
Survival rates for stage 3 lung cancer can vary between 13% to 36% depending on the subtype. Stage 3a lung cancer is often treated with surgery and medicines before or after surgery. Stage 3b and 3c ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results